What this is
- How it works
- How it works isn't classified yet
- Tested for
- Systemic Sclerosis
- Main trialPhase 3
- “The study will verify the superiority of MT-0551 to placebo at 26 weeks after treatment initiation in systemic sclerosis (SSc) patients using the modified Rodnan Total Skin thickness Score (mRTSS) as a measure of skin thickening. The safety and pharmacokinetics will also be investigated.”In the company’s words, NCT05198557 on ClinicalTrials.gov
- Other names
- Inebilizumab
Other drugs for Systemic Sclerosis
- AnifrolumabAstraZeneca · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- BMS-986353Bristol Myers Squibb · Phase 3
- CABA-201Cabaletta Bio · Phase 2/3
- BelimumabGSK · Phase 3
- NerandomilastBoehringer Ingelheim · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Jul 2025 | A Study of MT-0551 in Patients With Systemic Sclerosis | |
| Phase 2Authorised | not given | A PHASE-2B, DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE ACTIVITY AND SAFETY OF INEBILIZUMAB IN ANTI-NMDA RECEPTOR ENCEPHALITIS AND ASSESS MARKERS OF DISEASE (EXTINGUISH) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026